
## **IHCP** bulletin

**Note**: This bulletin is obsolete. Please see BT201021 for the updated version of this bulletin.

INDIANA HEALTH COVERAGE PROGRAMS BT201016 MAY 27, 2010



## **Changes to the Preferred Drug List**

Changes to the Preferred Drug List (PDL) were made at the May 21, 2010, Drug Utilization Review (DUR) Board meeting. These decisions are based on the recommendations from the Therapeutics Committee meeting held on May 7, 2010. Please refer to the table below for a summary of these changes. **The changes are effective July 1, 2010**.

The PDL and Smart PA<sup>™</sup> criteria can be accessed at <u>www.indianapbm.com</u> under Pharmacy Services. Notice of the DUR Board meetings and agendas are posted on the Family and Social Services Administration (FSSA) Web site at <u>http://www.state.in.us/fssa/</u>. Click "**More Events**" near the middle of the page to access the events calendar. Information about the Therapeutics Committee and the PDL is available at <u>http://www.indianapbm.com</u>.

Please direct prior authorization requests and questions about the PDL to the Affiliated Computer Services (ACS) Clinical Call Center at 1-866-879-0106. Please direct questions about this bulletin to HP Customer Assistance at (317) 655-3240 in the Indianapolis local area, or toll-free at 1-800-577-1278.

Drug Class	Drug	PDL Status
COX-II Inhibitors	Celebrex <sup>®</sup>	Non-Preferred with Smart PA criteria
Brand-Name Narcotics	buprenorphine sublingual tablets	Non-Preferred with PA criteria
Brand-Name Narcotics	fentanyl citrate lozenges	Non-Preferred with PA criteria
Brand-Name Narcotics	Onsolis™ buccal film	Non-Preferred with PA criteria

Continue